5 Result(s)

Article

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

Massimo Breccia, Elisabetta Abruzzese, Monica Bocchia, Massimiliano Bonifacio… in Leukemia (2020)

Article

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

Giovanni Caocci, Olga Mulas, Isabella Capodanno… in Blood Cancer Journal (2020)

Article

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper

BCR-ABL1 kinase domain (KD) mutation status is considered to be an important element of clinical decision algorithms for chronic myeloid leukemia (CML) patients who do not achieve an optimal response to tyrosine ...

Simona Soverini, Elisabetta Abruzzese, Monica Bocchia… in Journal of Hematology & Oncology (2019)

Article

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia

The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory hematological, cytogenetic ...

Michele Massimino, Stefania Stella, Elena Tirrò, Chiara Romano… in Molecular Cancer (2018)

Article

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation

SPARC is a matricellular glycoprotein with growth-inhibitory and antiangiogenic activity in some cell types. The study of this protein in hematopoietic malignancies led to conflicting reports about its role as...

Cesarina Giallongo, Piera La Cava, Daniele Tibullo, Ignazio Barbagallo… in BMC Cancer (2013)